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CONTROLLING YOUR DNA: PRIVACY CONCERNS IN 
GENOMIC TESTING AND THE UNCERTAINTY OF 
FEDERAL REGULATION AND LEGISLATION 
 
Sarah Washburn * 
 
 
I.  INTRODUCTION  
The headlines In November 2013, the United States Food and 
Drug Administration (FDA) issued a “cease and desist” order to the lead-
ing direct-to-consumer (DTC) genetic testing company 23andMe.1  In the 
warning letter, the FDA cited concerns about the public health conse-
quences of inaccurate test results and drastic measures patients could take 
due to a false positive or false negative test result.2  Though 23andMe has 
temporarily halted access to health-related genetic testing while it com-
plies with the FDA’s regulatory review process, they remain committed to 
ensuring consumers have direct access to their health information.3  
23andMe is one of many genetic testing companies with the belief that 
consumers have the right to access their genetic information and that this 
information can help people live longer, healthier lives.4  Open access to 
                                                            
* J.D. Candidate, DePaul University College of Law, 2016; B.S., Physics, DePaul University, 2010. I will 
begin my practice in patent law this Fall at Sughrue Mion in Washington D.C. I would like to thank 
Professor Josh Sarnoff for his comments and guidance in writing this Comment.  I would also like to thank 
Mike and Jane Washburn for their continuous support and encouragement.  
1 Nancy Fliesler, Direct-to-consumer genetic testing: a case of potential harm, VECTOR (May 5, 2014), 
http://vectorblog.org/2014/05/direct-to-consumer-genetic-testing-a-case-of-potential-harm/.  
2 U.S. Food and Drug Administration, 23andMe, Inc. 11/22/13, INSPECTIONS, COMPLIANCE, 
ENFORCEMENT, AND CRIMINAL INVESTIGATIONS, 
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm [hereinafter Warn-
ing Letter].  It should be noted that the warning letter points out that the FDA has been diligently working 
to help 23andMe comply with regulatory requirements regarding safety and effectiveness and obtain mar-
keting authorization but 23andMe has failed to complete the necessary studies and provide additional in-
formation requested by the FDA.  Id.  According to the letter, 23andMe has failed to even communicate 
with the FDA since May, six months prior to the issuance of the warning letter.  Id. 
3  Anne Wojcicki, An Update Regarding The FDA’s Letter to 23andMe, 23ANDMEBLOG (Nov. 26, 2013), 
http://blog.23andme.com/news/an-update-regarding-the-fdas-letter-to-23andme/. 
4 Id. Unfortunately many of these companies are no longer pure DTC companies. That is, many of these 
companies now require physician involvement in order for the consumer to obtain their genetic infor-
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genetic information will not only give individuals control over their health, 
but the research that flows from public genetic information will lead to a 
healthier society as a whole.  Over-reaching regulators and over burden-
some regulations will hinder that goal and inhibit potential scientific pro-
gress from free and accessible genetic information. 
 This Comment explores current regulation and proposed legisla-
tion within the field of genomic testing at both the federal and state level. 
It will also explore how such regulation and legislation affects the person-
alized medicine landscape for both the individual and the American public.  
I argue for a comprehensive regulatory plan that protects the privacy of 
genetic testing consumers without hindering an individual’s access to their 
own genetic information, as well as the public accessibility of genetic in-
formation for the purposes of scientific and medical advancement.  Part II 
provides an overview on the science of genetics, genomic sequencing, and 
the current state of personalized medicine, including the explosion in pop-
ularity of direct-to-consumer genetic services.  Part III explores the current 
regulatory landscape of DTC genomic testing and access to genomic in-
formation for research purposes on both the state and federal level.  I then 
argue that federal legislators and the FDA should assume a limited role in 
the control of genomic information obtained through open and voluntary 
consent as to foster innovation and the continued development of personal-




Throughout the last Genetic testing involves analyzing DNA, 
RNA, chromosomes, and proteins to detect minute variations that may be 
connected to various diseases and other health related issues.5  A genetic 
test can identify the carrier status for inherited disorders and make predic-
tions about disease risk and medication response.6  Genetic testing has the 
potential to be a powerful healthcare tool, but because the basic science 
behind it is widely misunderstood, its potential may be quashed through 
overzealous regulation or legislation based on unfounded fears.  Under-
                                                                                                                                               
mation. These companies include Pathway Genomics, Gene by Gene, and GeneDx, just to name a few. 
With 23andMe temporarily halting its health-related genetic testing services to consumers in 2013, no pure 
DTC companies currently exist. See infra note 84.   
5 Jessica Elizabeth Palmer, Genetic Gatekeepers: Regulating Direct-to-Consumer Genomic Services in an 
Era of Participatory Medicine, 67 FOOD DRUG L.J. 475, 478 (2012).  
6 Id. at 476.   
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standing the science of genetic testing is necessary to recognize both the 




A gene is the basic unit of heredity.8  Genes are made up of deoxy-
ribonucleic acid (DNA) and serve as instructions for making functional 
molecules such as ribonucleic acid (RNA) and proteins.9  Proteins have 
many functions within the body including performing chemical reactions 
and forming the cell’s structural components, but they cannot copy them-
selves.10  When a cell needs more proteins, it uses the manufacturing in-
structions coded in DNA.11  The DNA code of a gene is made up of a se-
quence of individual DNA building blocks, labeled A (adenine), T 
(thymine), C (cytosine) and G (guanine) – collectively called nucleo-
tides.12  The sequence of nucleotides within a gene gives the cell instruc-
tions on how to manufacture the necessary protein.13  Genes can vary in 
size from a few hundred DNA bases to more than 2 million bases.14  Genes 
are packaged tightly into structures called chromosomes.15  Every cell in 
the body contains a full set of chromosomes in the nucleus of the cell.16  A 
complete set of genes is called a genome.17  The human genome contains 
approximately 21,000 genes with three billion pairs of nucleotides.18  
While any two individuals’ DNA are 99.9% identical, the variations within 
the remaining 0.1% are responsible for the diversity among human be-
                                                            
7 Genomic testing is a probabilistic science as compared to a deterministic science.  Id.  That is, a genetic 
test merely describes the probability of a certain disease risk or medicine response.  “Reduced risk is not 
inconsistent with disease incidence.”  Kathryn Schleckser, Physician Participation in Direct-to-Consumer 
Genetic Testing: Pragmatism or Paternalism?, 26 HARV. J. LAW & TEC 695, 713-14 (2013).  An individual 
shown to have a decreased risk for a certain type of cancer may nevertheless develop that cancer.  Id.  That 
does not call into question the validity of the genetic test.  Id.   
8 U.S. Nat’l Library of Medicine, What is a gene?, GENETICS HOME REFERENCE, 
http://ghr.nlm.nih.gov/handbook/basics/gene (Jan. 11, 2016).  
9 Nat’l Institute of General Medical Sciences, Chapter 1: How Genes Work, THE NEW GENETICS, 
http://publications.nigms.nih.gov/thenewgenetics/chapter1.html (June 9, 2011).  
10 Id.  
11 Id.  
12 Id.  
13 Id.  
14 What is a gene?, supra note 8.   
15 Chapter 1: How Genes Work, supra note 9.  
16 Id.  Every cell normally contains 23 pairs of chromosomes, giving a total of 46 chromosomes per cell.  
U.S. Nat’l Library of Medicine, How many chromosomes do people have?, GENETICS HOME REFERENCE, 
http://ghr.nlm.nih.gov/handbook/basics/howmanychromosomes (Feb. 23, 2015).  Eggs, sperm, and red 
bloods cells are the exception.  Chapter 1: How Genes Work, supra note 9.  
17 Palmer, supra note 5, at 478.  
18 Id.  
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ings.19  Although these gene variations are what make each person unique, 




Genetic tests involve the analysis of DNA, RNA, chromosomes, or 
proteins in order to detect variations related to health and disease.21  Early 
advances in genetic medicine involved identification of disorders caused 
by inherited mutations in single genes such as cystic fibrosis, sickle-cell 
anemia, and Huntington’s disease.22  Huntington’s disease is a highly pen-
etrant disorder, meaning that almost all individuals with the mutated gene 
will eventually develop the disease.23  Thus, a genetic test for Huntington’s 
disease is highly predictive.24  Other disorders, such as cystic fibrosis, are 
significantly less penetrant.25  The presence of a mutated gene simply 
means that there is a possibility of developing a certain disease, but that 
possibility is dependent on other factors as well including the environment 
and family history.26   
 Some of the most common diseases are more complex and are not 
expressed by a mutation in a single gene.27  Disorders such as heart dis-
ease, obesity, addiction, and diabetes are influenced by a complex inter-
play of genetic and environmental factors.28  To identify the genetic basis 
for complex common diseases, genetic researchers began to study single 
nucleotide polymorphism (SNPs).29  The most common form of genetic 
variation between individuals, SNPs occur about once every 1,000 base 
pairs.30  SNPs are the 0.1% of base pairs in the genetic code that differ in 
each individual.31  SNPs are only classified as such if the variation occurs 
                                                            
19 Id. 
20 Nat’l Human Genome Research Institute, Regulation of Genetic Tests, National Institutes of Health, 
http://www.genome.gov/10002335 (Sept. 2, 2014).  
21 Palmer, supra note 5, at 478; Regulation of Genetic Tests, supra note 20.   
22 Palmer, supra note 5, at 478.  
23 Id.  
24 Id.  
25 Id.  
26 Id. 
27 Id. 
28 Palmer, supra note 5, at 478.   
29 In the scientific community, the acronym “SNPs” is colloquially pronounced “snips”. U.S. Nat’l Library 
of Medicine, What are single nucleotide polymorephisms (SNPs)?, GENETIC HOME REFERENCE, (January 
4, 2016), http://ghr.nlm.nih.gov/handbook/genomicresearch/snp.; Palmer, supra note 5, at 479.    
30 Jeffrey Perkel, SNP genotyping: six technologies that keyed a revolution, 5 NATURE METHODS 447 
(2008), http://www.nature.com/nmeth/journal/v5/n5/full/nmeth0508-447.html.  
31 Palmer, supra note 5, at 479.    
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in 1% or more of the population; otherwise the variation is a mutation.32  
SNPs can serve as landmarks in the search for genes associated with dis-
ease, drug response, and observable traits.33  Because a SNP-based screen 
can capture most of the genetic variation between individuals, comparing 
SNP data from many participants allows researchers to uncover small sta-
tistical associations between SNPs and various health conditions.34  More 
than a thousand genetic variants linked to common disorders have been 
identified in recent years.35  
 Even though SNPs make up only about one percent of the human 
genome, SNP-based testing can capture most genetic variation among in-
dividuals.36  Genetic tests are used to detect gene variants associated with a 
specific disease or condition.37  In the clinical setting, genetic tests can be 
used to determine the genetic cause of a disease, confirm a suspected diag-
nosis, predict future illness, detect the likelihood of passing on a gene mu-
tation, and predict response to therapy.38  A number of tests have been de-
veloped to perform complex analyses of multiple genes for chronic 
diseases such as heart disease and cancer, or to determine a patient’s risk 
of cancer reoccurrence.39  Genetic tests are also used to screen newborns, 
fetuses, or embryos used in in vitro fertilization for genetic defects.40  
They also have non-clinical uses such as paternity testing and forensics.41  
 Sequencing is the process of determining the exact order of the 
base pairs in a segment of DNA.42  Whole genome sequencing refers to the 
sequencing of the entire complement of DNA in an individual.43  Unlike 
SNP genotyping, which captures less than 0.1% of the genome, full ge-
nome sequencing is the complete DNA sequence of an individual.44  Vari-
ous techniques are utilized in whole genome sequencing including bacteri-
al artificial chromosome (BAC) based sequencing and more recently next-
                                                            
32 Perkel, supra note 30.  
33 Id.  
34 Palmer, supra note 5, at 479–80.  
35 Id.  
36 Id.  
37 Regulation of Genetic Tests, supra note 20.   
38 Id.  
39 Id. 
40 Id. 
41 Id.   
42 Illumina Sequencing Methods, ILLUMINA.COM 
http://applications.illumina.com/applications/sequencing.html; Nat’l Human Genome Research Institute, 
The Human Genome Project Completion: Frequently Asked Questions, NATIONAL INSTITUTES OF HEALTH, 
(Oct. 30, 2010), http://www.genome.gov/11006943.  
43 Id.  
44 Id.  
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generation sequencing (NGS).45  BAC-based sequencing involves cloning 
fragmented pieces of DNA in bacteria, amplifying the DNA.46  The BAC 
clones are then cut into still smaller fragments and loaded into a sequenc-
er.47  Computational methods are used to reassemble these short sequences 
into the entire sequence representing the human DNA.48 Recent advances 
in technology led to next-generation sequencing, enabling more rapid se-
quencing or larger stretches of DNA base pairs spanning entire genomes.49  
NGS involves identifying bases of a small fragment of DNA from signals 
emitted as each fragment is resynthesized using a known reference ge-




The Human Genome Project was a joint venture between the Na-
tional Institutes of Health (NIH) and the Department of Energy, along with 
international partners, to sequence all 3 billion base pairs in the human ge-
nome.52  The Project’s goal was to provide researchers with the tools to 
understand the genetic factors in human disease, paving the way for new 
strategies in diagnosis, treatment and prevention.53  The completed human 
sequence is a sort of map, a resource providing a set of detailed infor-
mation about the structure, organization, and function of the complete set 
of human genes.54  All data generated by the Human Genome Project was 
made available on the Internet, serving to accelerate the pace of medical 
discovery around the world.55  To date, the Project has fueled the discov-
ery of more than 1,800 disease genes, and at least 350 biotechnology-
                                                            
45 Nat’l Human Genome Research Institute, supra note 20; Illumina, An Introduction to Next-Generation 
Sequencing Technology, ILLUMINA.COM, (October 16, 2013), 
http://www.illumina.com/content/dam/illumina-
marketing/documents/products/illumina_sequencing_introduction.pdf. 
46 Id.  
47 Id. 
48 Id.  
49 Id.    
50 Illumina, supra note 45 at 4.  
51 Id.  
52 See generally, Nat’l Human Genome Research Institute, www.genome.gov; Human Genome Project, 
www.report.nih.gov. 
53 Human Genome Project, www.report.nih.gov.  
54 Nat’l Human Genome Research Institute, An Overview of the Human Genome Project, NATIONAL 
INSTITUTES OF HEALTH, (Nov. 8, 2012), http://www.genome.gov/12011238. 
55 Id. 
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based products resulting from the Human Genome Project are currently in 
clinical trials.56  
The Personal Genome Project was founded in 2005 and is dedicat-
ed to creating public genome, health, and trait data.57  While the Human 
Genome Project used only one anonymous individual for 70% of the final 
sequence and a number of different individuals for the remaining 30%, the 
Personal Genome Project aims to recruit as many as 100,000 individuals to 
contribute genomic sequence data, tissues, and extensive environmental, 
trait and other information to a publicly accessible and identifiable re-
search database.58  
There are currently more than 2,000 genetic tests for various hu-
man conditions.59  These tests enable patients to learn their genetic risks 
for disease and also help healthcare professionals to diagnose disease.60  
Having the complete sequence of the human genome is like having an in-
struction manual to the human body.61  The more researchers study this 
manual, the better they can understand human health and disease.62  A 
deeper understanding of disease at the genomic level will lead to a new 
generation of targeted interventions, including highly effective pharmaceu-
ticals with fewer side effects.63   
The Human Genome Project was a thirteen-year and nearly $3 bil-
lion effort.64 Today, the price for the sequencing of an entire human ge-
nome is under $5,000 and is continuing to fall.65  The NIH and other re-
search institutions are striving to bring the cost of sequencing an 
individual’s genome to $1,000 or less, increasing the availability of genet-
ic sequencing to consumers.66  One private sequencing technology compa-
ny, Illumina, recently announced that the company would begin producing 
                                                            
56 Research Portfolio Online Reporting Tools, Human Genome Project, NATIONAL INSTITUTES OF HEALTH, 
at https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx (Jan. 6, 2015).  
57 Jeantine E. Lunshof et al., Personal genomes in progress: from the Human Genome Project to the Per-
sonal Genome Project, DIALOGUES IN CLINICAL NEUROSCIENCE (Mar. 2010), available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181947/.  
58 Id.  
59 Understanding the Human Genome Project – A Fact Sheet, 8 NIH MEDLINEPLUS 15 (Spring 2013), at 
http://www.nlm.nih.gov/medlineplus/magazine/issues/summer13/articles/summer13pg15.html.  
60 Id.  
61 Nat’l Human Genome Research Institute, supra note 42.  
62 Id.  
63 Understanding the Human Genome Project – A Fact Sheet, supra note 59.   
64 Nat’l Human Genome Research Institute, supra note 42; Michael Malecek, Emerging Trends In Nucleic 
Acids And Human Genome Work, LAW 360, (Dec. 18, 2012); Trevor Woodage, Gatekeepers and Goal-
posts: The Need for a New Regulatory Paradigm for Whole Genome Sequence Results, 11 NW. J. TECH. & 
INTELL. PROP. 1 (2012).  
65 Malecek, supra note 64; Palmer, supra note 5, at 483. (“[T]he cost of whole genome sequencing…is ex-
pected to dip below the thousand-dollar mark soon”).  
66 See generally, Nat’l Human Genome Research Institute, supra note 42.  
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a new system this year that could sequence the full human genome for less 
than $1,000.67  Individualized analysis of a personal genome will lead to a 
powerful tool of preventive medicine.68  This new form of personalized 
health care will reshape preventative and diagnostic care to complement 
each individual based on his or her unique genetic code.69  Full genomic 
sequencing is not only important to individual patient care, but with the 
ability to sequence possibly millions of people, researchers will be able to 
truly understand how gene variants contribute to disease.70  This 
knowledge can then be used to develop more effective treatments and 
pharmaceuticals.71   
The data researchers currently use comes from people who have 
provided consent to the use of their genomes for projects such as the Hu-
man Genome Project and the Personal Genome Project.72  A controversy 
arises with the use of information paid for personally by individual direct-
to-consumer genetic testing consumers.  There is a debate on whether such 
personal genetic information should be available for use in supplemental 
research and the level of consent that should be required.   
 
Direct-to-Consumer Genomic Testing 
 
With the completion of the Human Genome Project in 2003, the 
interest in personal genetic information in the United States has increased 
exponentially.73  It became clear that Americans wanted access to their 
personal health blueprints, and as the cost of genetic testing plummeted, 
the direct-to-consumer (DTC) genetics industry emerged to meet this de-
mand.74  With several affordable choices available today, consumers can 
select a DTC provider, order a test kit online, send in a saliva sample, and 
then wait just a few weeks to gain access to the plethora of information 
contained in their very own unique genome.75  
                                                            
67 Erika Check Hayden, Is the $1000 genome for real?, NATURE (Jan. 15, 2014) (“If there was any doubt to 
if genomics would ever be able to reach the everyday man, at this price point and efficiencies it is absolute 
certainty.” quoting Michael Schatz).  
68 Understanding the Human Genome Project – A Fact Sheet, supra note 59.   
69 Palmer, supra note 5, at 481.  
70 Hayden, supra note 67.  
71 Id.  
72 See generally National Human Genome Research Institute, at www.genome.gov; (Jan. 7, 2016); Human 
Genome Project, at www.report.nih.gov. (Feb. 18, 2015).  
73 Schleckser, supra note 7, at 697.  
74 Id.  
75 Id.  
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Traditional genetic testing is done through a healthcare provider.76  
A patient who wants to be tested for disease risks or to determine if he or 
she is a carrier of a particular gene must see a doctor.77  The doctor will 
determine which tests, if any, are appropriate, collect samples, and send 
those samples to a laboratory.78  The laboratory returns the results to the 
doctor, who then interprets the results for the patient.79  However, DTC 
tests take the doctor out of the equation and gives control directly to the 
patient.80  
To some, most prominently regulation agencies, the absence of the 
learned intermediary has potentially unsafe consequences, with DTC com-
panies essentially providing unregulated medical diagnoses.81  Many of the 
commercial providers primarily market to people seeking to learn about 
their ancestry, but most of the recent controversy has been on those DTCs 
that provide health-related genomic services.82  The International Society 
of Genetic Genealogy currently lists twenty-five commercial testing pro-
viders.83  Of those twenty-five providers, only two currently list “health” 
as a purpose for the genetic testing services.84  Largely due to the threats of 
tough regulation, companies that emerged as leaders in the late 2000s such 
as deCODEme, Navigenics, and Pathway Genomics have widely fallen off 
the map.85 Under pressure by the FDA in 2010, Pathway Genomics and 
Navigenics quickly eliminated the customers’ ability to order tests without 
physician involvement.86  Then in 2012, both deCODEme and Navigenics 
                                                            
76 Id. at 698.  
77 Id. at 698-99.  
78 Id.  
79 Id. at 699.  
80 Id.  
81 See infra notes 111-16 and accompanying text.   
82 Palmer, supra note 5, at 483.  
83 List of DNA testing companies, at http://www.isogg.org/wiki/List_of_DNA_testing_companies. (Nov. 
11, 2015).   
84 Id. 23andMe and Gene by Gene are the two companies listed with “health” still listed as a function of the 
company.  23andMe has since ceased offering genetic reports due to FDA intervention.  See Warning U.S. 
FOOD AND DRUG ADMINISTRATION, supra note 2.  See also Anne Wojcicki, 23andMe Provides An Update 
Regarding FDA’s Review, 23ANDMEBLOG (December 5, 2013), http://blog.23andme.com/news/23andme-
provides-an-update-regarding-fdas-review/.;. INTERNATIONAL SOCIETY OF GENETIC GENEALOGY WIKI, 
supra note 83; Schleckser, supra note 7, at 700. 
85 Schleckser, supra note 7, at 700; see infra notes 110-25 and accompanying text. 
86 Schleckser, supra note 7 at 700; See also Dan Vorhaus et al., DTC Genetic Testing and the FDA: Is 
There an End in Sight to the Regulatory Uncertainty?, GENOMES UNZIPPED (June 16, 2011), 
http://www.genomesunzipped.org/2011/06/dtc-genetic-testing-and-the-fda-is-there-an-endin-sight-to-the-
regulatory-uncertainty.php#more-3681; The FDA sent Pathway Genomics a letter in 2010 stating that its 
Genetic Health Report was a medical device under the Act requiring FDA approval. U.S. Food and Drug 
Administration, Letter to Pathway Genomics Corporation Concerning the Pathway Genomics Genetic 
Health Report. 5/10/10, MEDICAL DEVICES, 
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm211866.htm. See infra note 123.  
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were acquired by biotech companies and left the DTC market.87  As a re-
sult, the genetic testing company 23andMe emerged as the undisputed 
leader in the DTC market. 88  
23andMe offers their genomic testing services for $99.89  Consum-
ers enroll via the website and purchase a DNA kit through the online 
store.90  The 23andMe kit arrives with detailed instructions.91  Following 
the instructions, customers spit two milliliters of saliva into a collection 
tube through an attached funnel.92  Closing the lid of the funnel releases 
the stabilization buffer into the collection tube.93  Then the funnel is re-
moved, a cap attached, and the tube is ready for shipping.94  The customer 
packs her sample into the prepaid box and drops it into a mailbox.95  
The saliva sample is sent to and processed by a clinical laboratory. 
96  The lab typically genotypes over one million SNPs and then “presents 
this SNP information to the consumer in the form of a personalized ge-
nomic report, which includes disease risk estimates, . . . pharmacogenomic 
information, carrier status for [select] heritable diseases, and . . . ancestry 
information.”97  23andMe results are typically available four to six weeks 
after [the] customer’s kit arrives at the laboratory.98  23andMe provided 
results for over 200 conditions ranging from earwax type and bitter taste 
perception to risk for Alzheimer’s disease and multiple sclerosis.99   
                                                            
87 Id.; Pathway Genomics today is still considered a DTC testing company even though it requires physi-
cian permission because it provides the information directly to the customer through its web portal.  
Schleckser, supra note 7, at footnote 30.   
88  Id.  
89 How it works, 23ANDME, https://www.23andme.com/howitworks/.  
90 Id.  
91 Providing your saliva sample, 23ANDME, https://customercare.23andme.com/hc/en-
us/articles/202904530-Providing-your-saliva-sample.  
92 Id.  
93 Id.  
94 Id.  
95 Id.  
96 Palmer, supra note 5, at 483-84; Schleckser, supra note 7, at 701.  
97 Palmer, supra note 5, at 484.  It is important to note that direct-to-consumer genetic tests like 23andMe 
are only examining predetermined locations on the genome – the SNPs – that are associated with particular 
traits.  See Schleckser, supra note 7, at 701.  In contrast, whole genome sequencing determines the precise 
sequence of all three billion base pairs in the individual genome.  Id.  Genotyping is currently much more 
cost effective but does have its disadvantages.  Id. at 702.  Since not all genetic variation takes the form of 
SNPs, genotyping misses many genetic variants present throughout the genome.  Id.  It cannot detect rare 
mutations, such as deletions or duplications of DNA, and in some populations, a given SNP may not be an 
accurate marker for a nearby mutation.  See Palmer, supra note 5, at 484.  As the cost of full genome se-
quencing continues to fall, genetic tests genotyping only SNPs will fall out of favor but until then the ability 
to access even a fraction of one’s genetic information for a reasonable price will still be attractive to con-
sumers.  
98 Schleckser, supra note 7, at 701.  
 
99 Id. at 703; Health Risks, 23ANDME, https://www.23andme.com/you/health/risk/.  
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23andMe used only those SNPs that were clinically validated in two or 
more research studies and agreed to collaborate with other DTC compa-
nies to develop a consensus in how to calculate disease risk predictions.100  
Each test listed in the health report is categorized according to the degree 
of scientific support for the relevant genetic association.101  The tests with 
the highest confidence are established research reports.102  They have been 
involved in multiple studies with over 750 participants or have the consen-
sus of the scientific community.103  Tests with less confidence are listed as 
being in the preliminary research stage and have been involved in one 
study of more than 750 participants.104  These tests are based on peer-
reviewed findings that have yet to be confirmed by the scientific commu-
nity.105  Tests with low confidence are also included and are described as 
preliminary research with the studies done involving less than 750 partici-
pants.106  Test results are presented graphically and numerically, display-
ing the customer’s risk as a percentage and comparing that risk to the av-
erage risk of the population.107  Similarly, drug response results are listed 
according to scientific validity and list the customer’s sensitivity to each 
drug compared to the average population.108  A customer can also down-
load his or her raw data into a text file, which includes each genotype at 
the approximately one million SNPs tested.109   
  
Efforts to Regulate DTC Testing 
 
The current state of DTC regulation is messy and unclear.110  
Three federal agencies that play a role in the regulation of genetic tests are 
Centers for Medicare and Medicaid Services (CMS), the Food and Drug 
Administration (FDA) and the Federal Trade Commission (FTC).111  CMS 
regulates all clinical laboratories performing genetic testing, ensuring their 
compliance with Clinical Laboratory Improvement Amendments of 1988 
                                                            
100 Palmer, supra note 5, at 485. 
101 Schleckser, supra note 7, at 703; Health Risks, supra note 99.  
102 Schleckser, supra note 7, at 703.  
103 Health Risks, supra note 99.    
104 Id.  
105 Schleckser, supra note 7, at 703.  
106 Health Risks, supra note 99.    
107 Schleckser, supra note 7, at 703. 
108 Drug Response, 23ANDME, https://www.23andme.com/you/health/drug_response/.  
109 Schleckser, supra note 7, at 703. 
110 Id. at 705 (“Regulation of DTC genetic testing is a hodgepodge at best”). 
111 Id.; NAT’L HUMAN GENOME RESEARCH INSTITUTE, supra note 20.  The FTC’s authority relates to how 
genetic tests are advertised.  Id.   
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(CLIA).112  The FDA has the broadest authority to regulate genetic tests as 
medical devices.113  Under the Federal Food, Drug and Cosmetic Act (the 
Act), the FDA has the power to review all new medical devices for safety 
and effectiveness.114  A medical device is defined in section 201(h) of the 
Act as a device intended for use in the diagnosis of disease or other condi-
tions, or in the cure, mitigation, treatment, or prevention of disease.115  The 
degree of FDA oversight of a genetic test is based on its intended use and 
the risks posed by an inaccurate test result.116  The agency categorizes 
medical devices into three separate classes: class I for low risk products, 
class II for moderate risk products, and class III for tests requiring the 
greatest level of scrutiny.117  Class III devices require premarket approval 
by the FDA.118 
In 2010, the FDA announced that it planned to regulate genetic 
testing, citing concerns in the growing separation between the commercial 
laboratories doing the testing and the physicians ordering the test.119  There 
were growing concerns that DTC genetic tests were medically unproven, 
meaningless, and misleading for consumers.120  Congress and the Gov-
ernment Accountability Office (GAO) also released reports that voiced 
concerns on the deceptive practices of DTC genetic tests, referring to the 
tests as “misleading and of little or not practical use.”121  That same year, 
                                                            
112 Id.  Congress passed CLIA in response to concerns about the quality of clinical laboratory testing.  
Woodage, supra note 64, at 4.  CLIA allowed CMS and CDC to implement standards for laboratory certifi-
cation.  Id.  These standards focus on quality control and quality assurance mechanisms with laboratories 
rather than the concerns about the clinical uses of test results.  Id.      
113 Regulation of Genetic Tests, supra note 20.   
114 Id.  
115 21 U.S.C. 321(h); FD&C Act 201(h).    
116 Regulation of Genetic Tests, supra note 20.   
117 Id.; See also 21 U.S.C. 360c (As device class increases from Class I, to Class II, to Class III, the regula-
tory controls also increase); Regulatory Controls, FOOD AND DRUG ADMINISTRATION, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/
ucm2005378.htm (June 26, 2014) (Class I devices are subject to the least regulatory control, and Class III 
devices are subject to the most stringent regulatory controls.  Id.  An example of a Class I device is a manu-
al toothbrush).  Compare with How to Study and Market Your Device, FOOD AND DRUG ADMINISTRATION, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm
, (Feb. 27, 2015) (An example of a Class II device is a non-invasive blood pressure monitors.  Id.  A heart 
value is classified as a Class III device).  Id.  
118 21 U.S.C. 360c(a)(1)(C).  
119 Regulation of Genetic Tests, supra note 20.  .  
120 Id.  
121 Id.; Palmer, supra note 5, at 493; (The 2010 report by the GAO is entitled “Direct-to-Consumer Genetic 
Tests: Misleading Test Results are Further Complicated by Deceptive Marketing and Other Questionable 
Practices” and identified ten egregious examples of deceptive marketing).  Kevin de Leon, Senate Appro-
priations Committee Fiscal Summary (May 20, 2013) http://leginfo.ca.gov/pub/13-14/bill/sen/sb_0201-
0250/sb_222_cfa_20130520_092108_sen_comm.html; DIRECT-TO-CONSUMER GENETIC TESTS: 
Misleading Test Resulting Are Further Complicated by Deceptive Marketing and Other Questionable Prac-
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the FDA began sending warning letters to DTC companies, notifying them 
that their services were medical devices subject to FDA regulation.122  The 
first such letter was sent to Pathway Genomics.123  Pathway had recently 
announced a marketing partnership with the drugstore chain Walgreens but 
the letter quickly caused Walgreens to back out and Pathway soon moved 
to a physician consent based business model.124  Twenty letters were sent 
out in 2010 to DTC testing companies, including 23andMe.125   
Either in spite of or in defiance to the FDA, 23andMe “pressed on 
under the shadow of possible regulation” until July 2012 when it decided 
to seek regulatory approval.126  23andMe announced that it submitted the 
first set of 510(k) documentation to the FDA.127  The application provided, 
according to 23andMe, a detailed description of the Person Genome Ser-
vice, extensive data supporting the performance of the technology, and 
comprehensive discussion of the science supporting the information pre-
sented to customers about their genetics and its impact on health.128  
23andMe remained committed to the belief that consumers have a funda-
mental right to their personal genetic data.129  Dissatisfied with the lack of 
cooperation by 23andMe, the FDA reiterated its policy that providing what 
                                                                                                                                               
tices, U.S. GOVERNMENT ACCOUNTABILITY OFFICE (July 22, 2010), available at  
http://www.gao.gov/products/GAO-10-847T. 
122 Schleckser, supra note 7, at 706.   
123 Palmer, supra note 5, at 493. See supra note 86.   
124 Id.  
125 Schleckser, supra note 7, at 706.   
126 Id. at 707. 
127 23andMe Takes First Step Toward Clearance, 23ANDMEBLOG (July 30, 2012), 
http://blog.23andme.com/news/23andme-takes-first-step-toward-fda-clearance/; See also Section 510(k) of 
the Food, Drug and Cosmetic Act requires device manufacturers to notify the FDA of their intent to market 
a medical device at least 90 days in advance. 510(k) Clearances, U.S. FOOD AND DRUG ADMINISTRATION 
(Jan. 13, 2015), at 
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/510k
Clearances/; 21 U.S.C. 360(k); FD&C Act 510(k).  Anyone who intends to market in the U.S. a Class I, II, 
or III device for human use, for which a Premarket Approval is not required, must submit a 510(k) submis-
sion to the FDA.  Premarket Notifications 510(k), U.S. FOOD AND DRUG ADMINISTRATION (Feb. 24, 2014), 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketS
ubmissions/PremarketNotification510k/default.htm#when.  A 510(k) is a premarket submission made to the 
FDA to demonstrate that the device is substantially equivalent to another legally marketed device.  Id.  That 
is, the device to be marketed must be at least as safe and effective as the comparable device currently on the 
market.  Id.  In the Warning Letter sent to 23andMe, the FDA indicated that the 510(k) mechanism is not 
appropriate because there are no substantially similar approved tests already on the market.  See Warning 
Letter, supra note 2; Gary Marchant, The FDA Could Set Personal Genetics Rights Back Decades, SLATE 
(Nov. 26, 2013 12:39 PM),  
http://www.slate.com/articles/technology/future_tense/2013/11/_23andme_fda_letter_premarket_approval_
requirement_could_kill_at_home_genetic.html.  The FDA determined the 23andMe must instead seek pre-
market approval or de novo classification of its tests.  Id. What The FDA Decision Means For 23andMe 
Customers, infra note 147.  
128 23andMe Takes First Step Toward Clearance, supra note 127.   
129 Id.  
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looks like disease diagnoses makes 23andMe’s service a medical device 
and thus is subject to FDA approval.130  The FDA ordered the company to 
discontinue marketing the Personal Genome Service.131   
As of December 5, 2013, 23andMe ceased offering new customers 
access to health-related genetic tests pursuant to an FDA’s directive.132  
Customers who had purchased kits before November 22, 2013 continue to 
have access to health reports previously provided by 23andMe, but any 
DNA kits purchased after that date have access only to ancestry-related in-
formation and their raw data without interpretation of that data by 
23andMe.133  In a letter dated November 22, 2013 the FDA warned 
23andMe that the company was marketing its Personal Genome Service 
without marketing clearance or approval in violation of the Act.134  The 
FDA has classified the Saliva Collection Kit as a medical device within 
the meaning of the Act because it is intended for use in the diagnosis of 
disease or other conditions, or in the cure, mitigation, treatment, or preven-
tion of disease, or is intended to affect the structure or function of the 
body.135  The FDA quotes language from the 23andMe website and says 
that most of the intended uses for the Personal Genome Service listed on 
the website, for example health reports providing “health risks,” “carrier 
status,” “drug response,” and “first step in prevention” that enables users 
to “take steps toward mitigating serious diseases” are medical device uses 
under the Act.136  These uses require premarket approval from the FDA.137  
The FDA cites some of these uses as particularly concerning because of 
the potential health consequences.138  In particular the FDA believes that 
assessments for the BReast CAncer susceptibility gene (BRCA)-related 
genetic risk and drug responses could lead a patient to take unnecessary 
drastic measures based on a false positive or fail to recognize an actual risk 
that may exist based on a false negative.139  The FDA says that it has no 
assurance that the company has analytically or clinically validated the Per-
                                                            
130 Id. (The FDA also did not care for 23andMe’s plan for an expanded marketing effort, including a 
planned television ad campaign).  Robert Hof, Seven Months After FDA Slapdown, 23andMe Returns With 
New Health Report Submission, FORBES (June 20, 2014), 
http://www.forbes.com/sites/roberthof/2014/06/20/seven-months-after-fda-slapdown-23andme-returns-
with-new-health-report-submission/. 
131 Warning Letter, supra note 2; Hof, supra note 130.   
132 Wojcicki, supra note 84.  
133 Id.  November 22, 2013 is the date of the warning letter sent by the FDA.  
134 Warning Letter, supra note 2.   
135 Id.  
136 Id.  
137 Id.  
138 Id.  
139 Warning Letter, supra note 2.   
18#1_WASHBURN  REVISED.DOC (DO NOT DELETE) 3/1/16 11:50 AM 
2016]   CONTROLLING YOUR DNA           15 
 
sonal Genome Service for its intended uses and thus must discontinue 
marketing the PGS until it receives the proper authorization from the 
agency.140   
The FDA and 23andMe came to an agreement that the genetic test-
ing company could continue to sell the test on the condition that it provid-
ed only raw genetic data and ancestry information, not health reports.141  
With this discontinuance in service, people have few options to obtain a 
health report based on their genetic information.142  In essence, this sort of 
regulation has caused pure DTC testing to cease to exist.143  23andMe 
agreed to go through the long and arduous FDA approval process.144  
However, this has been a significant step backward in an individual’s con-
trol of their genetic information and a step toward FDA regulation of ge-
netic information.  The agency’s designation of 23andMe’s service as a 
medical device inhibits the consumer from accessing his or her own genet-
ic information without the permission of a learned intermediary.145 Until 
23andMe can gain approval for each of its more than 200 genetic tests, 





The FDA and associated regulatory agencies need to develop a 
comprehensive regulatory plan that addresses the issues it raises regarding 
consumer safety and privacy without unnecessarily restricting an individu-
al’s right to his personal information and trampling a potentially vastly 
useful and significant DTC genetic testing market.  The first section argues 
                                                            
140 Id.  
141 Wojcicki, supra note 84   
142 Promethease – Genetic Health Information Alternative, DNAEXPLAINED – GENETIC GENEALOGY (Dec. 
30, 2013), http://dna-explained.com/2013/12/30/promethease-genetic-health-information-alternative/.  
(Third parties offering interpretive reports such as Promethease have emerged in the market to fill this new 
void. At Promethease people can upload the text file obtained from any DTC testing service including 
23andMe.  They will process the raw data and provide the customer with a report that is available for 
download from the server).  
143 Schleckser, supra note 7, at 705. 
144 Wojcicki, supra note 3.  
145 Schleckser, supra note 7, at 707.   
146 Anne Wojcicki, A Note to Our Customers Regarding the FDA, 23ANDME BLOG (Dec. 23, 2015), 
http://blog.23andme.com/news/a-note-to-our-customers-regarding-the-fda/. (On February 19, 2015, the 
FDA granted authorization to 23andMe to market the Bloom Syndrome Carrier Status report, the first such 
authorization granted to any DTC genetic test. This gives 23andMe a regulatory framework for future sub-
missions.  Because 23andMe successfully gained authorization from the agency, it may be able to submit 
some future submission through the standard 510(k) pathway as opposed to the much more stringent de 
novo review). What The FDA Decision Means For 23andMe Customers, 23ANDME BLOG (Feb. 19, 2015), 
http://blog.23andme.com/news/what-the-fda-decision-means-for-23andme-customers/.  
18#1_WASHBURN  REVISED.DOC (DO NOT DELETE) 3/1/16 11:50 AM 
16              DEPAUL JOURNAL OF HEALTH CARE LAW [VOL. 18.1:1 
 
for the necessity of freely accessible genetic information and its benefits to 
both individual consumers and patients and society as a whole because its 
promise to transform healthcare as we know it.  The next section then ex-
plores the concerns about DTC genetic testing put forth by both regulatory 
agencies and legislators and attempts to explain why many of these con-
cerns are both shortsighted and heavy-handed, largely doing more to stifle 
the genetic testing industry rather than protect consumers.  Nevertheless, 
valid concerns do exist in the DTC genetic testing landscape that can be 
addressed in such a way as to both protect consumers and promote scien-
tific innovation, benefiting all of society.  Lastly, I argue that the Ge-
nomics and Personalized Medicine Act (GPMA), originally introduced in 
2006, is a suitable starting point for legislation aiming to protect consum-
ers while expanding and accelerating beneficial genomics research.   
 
The Need For Open Accessibility of Genetic Information 
 
To use whole genome sequencing to uncover changes in DNA that 
underlie disease, scientists and clinicians need access to whole genome se-
quence data from many individuals.147  Continued advances in healthcare 
depend on large numbers of individuals willing to share their data for re-
search purposes.148  Additional health and demographic information on 
each individual further aid researchers in making connections between var-
iations in whole genome sequence data and specific diseases.149  Public se-
quencing projects like the Personal Genome Project rely on public partici-
pation for their success.150  The PGP’s model is based on open consent and 
public data access to further human genomic research.151  Data sets and 
tissue samples from the project are made publicly available with minimal 
or no access restrictions and can generally be transferred to outside re-
search studies to be utilized by and combined with data from third par-
ties.152 This organized effect is essential to the success of genomic re-
search.153 
The DTC genetic testing company 23andMe is not just a place for 
customers to learn about their own ancestry and genetic predisposition to 
                                                            
147 Presidential Commission for the Study of Bioethical Issues, Privacy and Progress in Whole Genome 
Sequencing, page 16 (2012),  
148 Id.   
149 Id.  
150 Jeantine E. Lunshof et al., Personal genomes in progress: from the Human Genome Project to the Per-
sonal Genome Project  12(1) DIALOGUES IN CLINICAL NEUROSCIENCE 47, 47-60 (Mar. 2010).  
151 Id.  
152 Id.  
153 Id.  
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diseases, it has also become one of the largest databases of personal genet-
ics information in the world.154  23andMe has a substantial research arm 
and has done significant medical research with the database of genetic in-
formation it has built.155  They are also able to offer the genetic data of 
700,000 people to researchers and pharmaceutical companies to conduct 
large-scale medical studies that would normally take months or years to 
solicit enough volunteers.156  23andMe offers customers the opportunity to 
participate in genetic research at the time they purchase the testing kit.157  
23andMe asserts that its customers who consent to research contribute to 
over 230 studies.158  The company has identified hundreds of new genetic 
associations.159 The more innocuous include whether a person is likely to 
sneeze when looking at a bright light or whether a person can smell aspar-
agus in his urine to.160  More promising research includes the company’s 
recent findings on Parkinson’s disease.  
A study with more than 10,000 participants has identified two new 
genetic associations for the disease.161  This led to 23andMe’s first patent 
in May 2012 entitled “Polymorphisms Associated With Parkinson’s Dis-
ease.”162  The patent relates to the discovery of a variant in the SGK1 gene 
that may be protective against Parkinson’s disease in individuals who car-
ry the rare risk-associated LRRK2 G2019S mutation.163  In its announce-
ment of the patent, 23andMe emphasizes its belief that patents should not 
be used to obstruct research and maintains that obtaining a patent is an im-
portant step in ensuring its genetic breakthroughs translate into real-world 
benefits.164  Patents are important for biotechnology or pharmaceutical 
companies as they provide assurance for the large financial investment re-
quired in the resource-intensive process of drug development.165  23andMe 
goes on to say that its patent will not prevent other entities from accessing 
the genetic data or its interpretation specific to its patents.166  Third parties 
                                                            
154 Heather Somerville, 23andMe aims to be Google for genetic research, SAN JOSE MERCURY NEWS Sept. 
6, 2014. .  
155 23andMe, Get involved in a new way of doing research, at, https://www.23andme.com/research/.  
156 Somerville, supra note 154.   
157 23andMe, supra note 155.  
158 Id.  
159 Id.   
160 Charles Seife, 23andMe Is Terrifying, but Not for the Reasons the FDA Thinks (Nov. 27, 2013) at 
http://www.scientificamerican.com/article/23andme-is-terrifying-but-not-for-reasons-fda/.  
161 23andMe, supra note 155. 
162 Anne Wojcicki, Announcing 23andMe’s First Patent, 23ANDMEBLOG (Mar. 28, 2012), at 
http://blog.23andme.com/news/announcements/announcing-23andmes-first-patent/.  
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can continue to use the genetic information without licensing fees, further-
ing their stated belief that meaningful research based genetic information 
is their primary mission.167   
 
Concerns in the DTC Genetic Testing Industry 
 
Concerned with the privacy of individual participants, recent state 
legislation has attempted to curb the wide availability of this infor-
mation.168  Several states have attempted to enact legislation pertaining to 
the privacy of genetic information.169  For example, the Genetic Infor-
mation Privacy Act in California proposed by California State Senator 
Alex Padilla attempts to regulate what DTC companies can and cannot do 
with the genetic information of its customers.170  Similar bills have passed 
in other states, including Illinois, but the range of protections differs from 
state to state.171  California’s proposed bill is of particular interest because 
there is currently no protection of genetic privacy outside of the health 
care system and the booming biotech industry in the state is vocal about 
how this type of legislation could slow the progress of research and clini-
cal trials.172  The bill addresses concerns over DTC genetic testing compa-
nies that allow consumers to submit genetic samples in order to test for 
genetic disorders, obtain ancestral information, or participate in research 
studies.173   
Currently, the federal Health Insurance Portability and Accounta-
bility Act (HIPAA) protects the genetic and personal health information of 
                                                            
167 Id. 
168 Jessica Shugart, California bill would prevent genetic-testing firms from using surreptitiously obtained 
DNA, SAN JOSE MERCURY NEWS (May 23, 2013).  
169 Id.  Over 30 states have some sort of laws in place providing protection against the collection or sharing 
of genetic data.  Id.  The laws range from protecting the privacy of health-related ge-
netic information to treating all DNA as private property.  Id.  Specifically, 27 states 
require consent to disclose genetic information.  Genetic Privacy Laws, National 
Conference of State Legislatures, http://www.ncsl.org/research/health/genetic-
privacy-laws.aspx (Jan. 2008).  Five states explicitly define genetic information as 
private property.  Id.  Four states mandate individual access to personal genetic in-
formation.  Id.  Nineteen states have established penalties, civil and criminal and in 
some cases both, for violating genetic privacy laws.  Id.   
170 Id.; Senator Kevin de Leon, Senate Appropriations Committee Fiscal Summary, Bill Analysis (January 
23, 2014); California Senate Bill 222 and Senate Committee Reports, available at 
http://leginfo.ca.gov/pub/13-14/bill/sen/sb_0201-0250/sb_222_cfa_20140123_091418_sen_comm.html; 
California Senate Bill 1267 and Senate Committee Reports; Chandi Abeygunawardana, Governing The 
Code Of Life: Calif.’s DNA Privacy Bill, LAW 360 (June 6, 2012). 
171 Shugart, supra note 168. See also Genetic Privacy Laws, supra note 169.  
172 Shugart, supra note 168; Helen Shen, California considers DNA privacy law, NATURE (May 18, 2012), 
http://www.nature.com/news/california-considers-dna-privacy-law-1.10677.  
173 Kevin de Leon, Senate Appropriations Committee Fiscal Summary (May 20, 2013), 
http://leginfo.ca.gov/pub/13-14/bill/sen/sb_0201-0250/sb_222_cfa_20130520_092108_sen_comm.html.  
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patients but Senator Padilla maintains that the laws do not protect people 
against companies outside the health care system.174  The Senate Appro-
priations Committee analysis of Senator Padilla’s bill cites the GAO report 
that identifies deceptive marketing practices and misleading test results.175  
If passed, the bill would prohibit any person from “obtaining, analyzing, 
retaining, or disclosing genetic information without the written authoriza-
tion of the individual to whom the information pertains” under the threat 
of civil and criminal penalties.176  The bill includes exceptions such as for 
a hospital, laboratory, or physician carrying out court-ordered tests, a li-
censed health care professional, and any person that is already required to 
comply with HIPAA.177  DTC companies are specifically excluded from 
the exhaustive list of exemptions.178  
 The University of California and other major research universities 
argue that these exceptions do not go far enough and could have a costly 
and damaging effect on research.179  The university wrote a formal letter to 
the California legislature objecting to the bill.180  Under the proposed legis-
lation, an individual’s genetic information may only be used by individuals 
specifically named on a consent form and only for purposes given on the 
consent form.181  A genomic dataset could not be re-used in separate ex-
periments or be made available to third-parties for further research.182  Re-
searchers must either destroy the data after each study or obtain new con-
sent from individual participants, an infeasible task for studies involving 
thousands of subjects.183   
Geneticist David Segal, associate director of genomics at the Uni-
versity of California, Davis, believes such requirements could seriously 
hinder genomic research.184  By being forced to re-obtain consent, Califor-
nia universities would essentially be barred from doing such large genomic 
studies.185  The university estimates the provisions of the bill could in-
crease central research and hospital administrative costs approximately 
$40 million per year.186  The costs result from the increased workload as-
                                                            
174 Shugart, supra note 168. 
175 Kevin de Leon, supra note 170.  
176 Id.  
177 Kevin de Leon, supra note 173.   
178 Id.  
179 Shugart, supra note 168. 
180 Shen, supra note 172. 
181 Id.  
182 Id.  
183 Id.  
184 Id.  
185 Id.  
186 Kevin de Leon, supra note 173.   
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sociated with obtaining authorizations for research not covered by the ex-
ceptions enumerated in the bill.187   
The University of California is also concerned that the state’s bio-
medical industry could be put at a distinct competitive disadvantage for 
public and private research grants.188  To the extent research involving ge-
nomic data could become more difficult to conduct due to the added level 
of consent, financiers could look to other states with less red tape.189  A re-
duction in research grants could result in a loss of millions of dollars in re-
search funding for institutions within the state.190  Supporters of the bill 
maintain that the bill does not prevent institutions from doing research and 
that it simply adds a level of consent but the added level of consent is 
over-burdensome.191  University of California policies governing human 
research already require informed consent when using genomic data.192  
Genetic information is also typically identified by number rather than by 
an individual’s name.193  Under the bill, even anonymous data would re-
quire re-authorization for re-use.194  The first attempt to pass similar legis-
lation stalled in 2012 in the Appropriations Committee.195  The new ver-
sion of the bill was introduced in February 2013 and is currently pending 
in the Senate.196   
23andMe, a California based company, has similar concerns to the 
University of California and other research institutions as to the detri-
mental effects of the genetic privacy bill.197  23andMe requires customer 
consent for research participation.198  Research participation is an opt-in 
choice during the kit registration process and customers can opt-out of fu-
ture research at any time through his account.199  The consent forms and 
privacy policy clearly state that its customers’ genomic information is used 
for research by 23andMe and may be disclosed to third parties for outside 
                                                            
187 Id.  
188 Shugart, supra note 168; Shen, supra note 172. 
189 Kevin de Leon, supra note 173.   
190 Id.  
191 Shen, supra note 172. 
192 Id.  
193 Id.  
194 Id.  
195 Shugart, supra note 168. 
196 S.B. No. 222. Complete Bill History, available at http://leginfo.ca.gov/pub/13-14/bill/sen/sb_0201-
0250/sb_222_bill_20140203_history.html; See also Washington State Legislature, at Overview of the Leg-
islative Process, http://www.leg.wa.gov/legislature/Pages/Overview.aspx.  The bill can then be reintro-
duced and retained in its present position.  Id.  At this time it does not seem that the bill has been reintro-
duced.  
197 Shugart, supra note 168. 
198 See generally Get involved in a new way of doing research, supra note 155.  
199 Id.  
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research studies.200  23andMe explains that basic research consent means 
that the customer’s genetic and self-reported information may be used in 
an aggregated form, stripped of identifying registration information for 
peer-reviewed scientific research.201  The company may disclose individu-
al-level personal information to a third party only through an additional 
level of consent given by the customer.202  The customer can choose to 
have his DNA sample discarded to further ensure his privacy.203  Custom-
ers also have the option of simply receiving their raw genetic data with no 
analysis.204  They can then take that raw data file to alternative companies 
such as Promethease.205  Promethease will process the raw data and then 
the raw data file is deleted within 24 hours of completion of the health re-
port, providing additional security to those that wish to receive their health 
report but not to share their genetic information.206    
Individuals who freely give their consent to companies such as 
23andMe or public projects such as the Personal Genome Project and wish 
to contribute to the beneficial research taking place should not be prohibit-
ed from doing so.  Senator Padilla cites concerns with specific genetic test-
ing companies that make no attempt to discourage customers from secretly 
sending in another’s genetic sample.207  The Illinois based company 
EasyDNA encourages customers to send “discreet samples” such as hair, 
clothing, or cigarette butts when it is not possible to directly obtain sample 
from the individual to be tested.208  Companies that aim to surreptitiously 
obtain DNA for nefarious reasons should be prohibited from doing so 
through regulation but said regulation should not impede those doing ben-
eficial research or hinder individuals’ ability to discover and use their own 
genomic data for their benefit.209  23andMe requires that the person sub-
mitting the DNA sample has legal authorization to do.210  Although all 
consent forms are filled out online, the testing kit requires eight milliliters 
of saliva.211  A sample of that size usually takes a customer five to ten 
minutes to gather, greatly minimizing the likelihood that amount of saliva 
                                                            
200 23andMe, Privacy Statement, (Dec. 7, 2015), https://www.23andme.com/legal/privacy/. 
201 Id.  
202 Id.  
203 Id.  
204 Get involved in a new way of doing research, supra note 155; Promethease privacy, SNPEDIA, (Mar. 25, 
2014), at http://www.snpedia.com/index.php/Promethease/privacy 
205 Promethease privacy, supra note 204.  
206 Id.  
207 Shugart, supra note 168. 
208 Id.  
209 Id. at 3. (discussing research concerns in light of potential regulation).   
210 Id.  
211 Id. 
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could be secretly collected from another. 23andMe does not perform pa-
ternity or infidelity testing.212  There needs to be a distinction between ge-
netic testing obtained by individuals that wish to gain knowledge about 
their personal health and predisposition to cancer, diabetes, Parkinson’s 
and a host of other diseases and the more deceitful uses of genetic testing 
such as paternity testing without consent and “infidelity testing” in which 
the underwear of an allegedly unfaithful partner is secretly tested for for-
eign genetic material.213  
 
Immediate Concerns for the DTC Genetic Testing Consumer 
 
Many opponents of public access to personal genetic data, includ-
ing the FDA, cite concerns about the misuse of this data ranging from the 
plausible to fanciful.214  The FDA in particular is concerned that physi-
cians have been removed from the equation and consumers now have di-
rect access to their genetic information straight from the testing facility.215  
The FDA believes that marketing directly to consumers can increase the 
risk to the consumer because of the possibility patients may make a deci-
sion that adversely affects their health based on the information received 
from genetic reports.216  This stems from the FDA’s patent mistrust of the 
accuracy of genetic tests being offered to consumers through DTC test-
ing.217  
The FDA has a legitimate concern in companies making high-risk 
claims to their customers such as their risk for cancer or their likelihood of 
responding to a specific drug.218  Companies certainly should not be mak-
ing arbitrary determinations or allowing customers to rely on false or mis-
leading marketing to make consumers believe tests are more reliable than 
they actually are.  However, this concern should not bar consumers from 
gaining access to their genetic information without the consent of a physi-
cian.  Rather the FDA, along with the other participating agencies, can al-
leviate this concern through proper regulation and strict enforcement for 
                                                            
212 Shugart, supra note 168. 
213 Id.   
214 Direct-to-Consumer Genetic Testing and the Consequences to the Public: Hearing before the Subcomm. 
on Oversight and Investigations of the Comm. On Energy and Commerce, 111th Cong., 68-82 (.2d Sess. 
2010) [hereinafter Prepared Statement by Shuren] (statement of Jeffrey Shuren, M.D., Dir. of the Center for 
Devices and Radiological Health, Fed. Drug Admin.) (describing the potential effects of direct-to-consumer 
testing). 
215 Id.  
216 Id at 79.  
217 Id.  
218 Id.  
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companies not in compliance.  The FDA believes that giving this type of 
information directly to the consumer can cause the consumer to make a 
rash decision such as stopping or changing the dose of a medication or 
continuing an unhealthy lifestyle.219  To reach such a conclusion is drastic 
and farfetched.  This is especially clear in the BRCA-related genetic risk 
example the FDA likes to use in its Warning Letters.220  The FDA is con-
cerned that consumers that receive a false positive (the genetic test showed 
the presence of a BRCA1 or BRCA2 genetic mutation that can cause can-
cer) will take unnecessary measures such a prophylactic mastectomy, 
chemoprevention or other “morbidity-inducing actions.”221  What the FDA 
either fails to recognize and conveniently overlooks is that no consumer 
who learns they do have mutations in either the BRCA1 or BRCA2 genes 
is going to take “morbidity-inducing actions” without first consulting with 
a physician. These types of drastic measures must be performed by trained 
physicians and thus a doctor as an intermediary is still present in the pro-
cess.  A doctor retains the ability to relay information to the patient and 
advise the patient on the reliability of such tests and the likelihood of false 
positives.  A doctor may even recommended a second test to confirm.  
There is no reason to assume that a consumer cannot responsibly control 
his or her health decisions after receiving a genetic report from a DTC ge-
netic testing service.  
The report from 23andMe is also informative to the consumer and 
ensures the consumer understands the limitations of the report.222  The ge-
netic test from BRCA1 and BRCA2 mutations is listed as an established 
research report, a test with the highest confidence and support of the scien-
tific community.223  However, the report goes on to explain that the BRCA 
mutations covered in the report are only three of hundreds in the BRCA1 
and BRCA2 genes that can cause cancer.224  The absence of the mutations 
tested in the 23andMe genetic report does not rule out the possibility of 
other mutations that increase the risk of the disease.225  Further, only five 
to ten percent of breast cancers occur in women with a genetic predisposi-
                                                            
219 Prepared Statement by Shuren, supra note 214. 
220 Warning Letter, supra note 2.  
221 Id.  
222 Inherited Conditions, BRCA Cancer Mutations, 23andMe, at 
https://www.23andme.com/you/journal/brca/overview/.  
223 Id.; See supra notes 101-03 and accompanying text.   
224 Id. 23andMe provides data for only three specific cancer-associated mutations because these three muta-
tions account for 80-90% of all hereditary breast and ovarian cancers cases in people with Ashkenazi Jew-
ish ancestry.  Id.  A powerful predictive tool, about 50-60% of women who have one of these three muta-
tions will develop breast cancer. Id.   
225 Id. About one in eight women with one of the three mutations will still develop breast cancer.   
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tion for the disease, usually due to mutation in either the BRCA1 or BRCA 
2 genes.226  Many other factors can contribute to the likelihood of develop-
ing breast cancer including family history and environmental factors.227  
Given the amount of information 23andMe provides, it is unlikely even a 
false negative would cause a consumer to fail to take or continue to take 
preventative measures in his or her healthcare.   
Similarly, the FDA’s concern with consumers self-managing their 
prescription medicine based on the drug response assessment is unfound-
ed. Genetic reports on drug responses from 23andMe assess the likelihood 
of a consumer’s sensitivity to certain prescription drugs.228  For example, 
the 23andMe genetic report tests an individual’s sensitivity to the generic 
drug warfarin.229 Warfarin is an anticoagulant used to treat and prevent 
blood clots.230  Finding a patient’s optimal dose of this life-saving drug is 
notoriously difficult.231  This kind of genetic information can help a doctor 
determine the initial dose of the drug.232  The 23andMe report explains that 
there are many genetic and non-genetic factors that can affect how the 
body responds to warfarin.233  A doctor takes into account several other 
factors including age, sex, weight, and diet when selecting the initial dose 
of warfarin.234  Throughout the Warfarin Sensitivity Report, 23andMe in-
structs consumers to continue taking their medication as directed and 
enunciates that the information should be used in consultation with their 
physician.235  
23andMe is an example of the way DTC genetic testing services 
should be run.  The model 23andMe established is the model the FDA 
should emulate when designing regulations for future DTC testing compa-
nies.  Their reports provide reliable information while responsibly dissem-
inating that information to consumers.  The ability of individuals to obtain 
reports that include over 200 tests for under $100 is a valuable tool in the 
                                                            
226 Id.  
227 Id.  
228 23andMeDrug, supra note 108.    
22923andMe, Drug Response> Warfarin (Coumadin®) Sensitivity, available at 
http://www.23andme.com/you/journal/warfarin/overview/. An overview of the drug Warfarin (Couma-
din®). This test is also based on established research, fully supported by the scientific community.  
230 Id.  
231 Id.  
232 Id.  
233 Id.  
234 Id. 
235 Id. (“If you are taking warfarin, keep taking it as directed by your doctor;” “Consult with a healthcare 
provider about confirming the result of taking appropriate next steps;” “Do not use the information in this 
report on its own to stop, start, or mark any changes to any current treatment without first consulting a 
healthcare provided.”)  Id.   
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continuing healthcare revolution in the United States.236  The ability for 
consumers to obtain such valuable information without the requirement of 
a physician as an intermediary is essential to an individual’s ability to be 
proactive about their own healthcare.  Again, these reports are a tool peo-
ple are using to reclaim control over their health.  It is not to say that a 
learned physician is not an important and vital part of the healthcare pro-
cess.  It is essential that the DTC genetic testing industry work in conjunc-
tion with the healthcare community to ensure maximum benefit to society.    
 
Concerns with Public Access to Genetic Information 
 
There are of course risks associated with the publication of an in-
dividual’s genetic data.237  Many of these risks can be mitigated through 
the proper legislation including requiring strict privacy controls and strong 
security practices.  As risks are inherent in society though, some threats 
will always remain.  Both 23andMe and public genome databases like the 
Personal Genome Project disclose these risks in its consent forms.238  
Risks associated with public disclosure include adverse affects on the em-
ployment, insurance and financial well being due to discrimination based 
on information discovered in a person’s genetic data.239  There is also a 
possibility of a security breach wherein personal data, not intended to be 
published, could become public.  The possible scenarios for nefarious uses 
of pubic data are boundless.  Like an episode of CSI, some tech savvy of-
fender could take a DNA sequence data and make synthetic DNA to plant 
at a crime scene, implicating some oblivious participant in the crime.   
Though these risks are real and should be addressed by the FDA 
and other enforcement agencies, they pale in comparison to the benefits of 
the availability of a large public database for research purposes.  Each par-
ticipate consents to these risks when he or she chooses to sign the consent 
forms and publically share genetic data.  Participants choose to share their 
personal data in hopes of making meaningful scientific contributions.  Be-
cause of individual participation, society as a whole reaps the benefits of 
research and the resulting scientific advancement.  
                                                            
236 Health Risks, supra note 99; How it works, supra note 89.   
237 Harvard Med. Sch., Personal Genome Project (updated Dec. 13, 2011) available at 
http://www.personalgenomes.org/static/docs/harvard/PGP_Consent_Approved_02212013.pdf; 23andMe, 
Research Consent Document, https://www.23andme.com/about/consent/.  
238 Research Consent Document, supra note 237.  
239 Id. at 13.  (Such a risk has been addressed in the Genetic Information Nondiscriminatory Act (GINA). 
GINA prohibits individuals from discrimination by health insurers or employers based on genetic infor-
mation.  42 U.S.C. § 2000ff (2014).  The law does not apply to the use of genetic information in all circum-
stances.  
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Proposed Legislation Based on the GPMA 
 
While there is a need for appropriate regulation to protect consum-
ers and patients, there is an equally pressing need to avoid creating a sys-
tem of oversight that would be an obstacle to the continued growth of per-
sonalized medicine.240  Encouraging the advancement of genomic research 
while ensuring individuals are adequately protected from deceptive prac-
tices of genomic testing companies through regulation involves a delicate 
balance.  The Genomics and Personalized Medicine Act (GPMA) was 
originally introduced in 2006 by then-Senator Barack Obama and was re-
introduced in 2010 by Congressman Patrick Kennedy.241  Though the bill 
died in committee,242 it was a promising start on regulation that would pro-
tect individuals but not stifle innovation.  The bill aimed to strike a balance 
between consumer protection and flexibility for companies and research 
institutions.243  The bill’s stated purpose was “to secure the promise of per-
sonalized medicine for all Americans by expanding and accelerating ge-
nomics research and initiatives to improve the accuracy of disease diagno-
sis, increase the safety of drugs, and identify novel treatments, and for 
other purposes.”244  The bill established an Office of Personalized 
Healthcare (OPH) within the Department of Health and Human Services 
(HHS).245  The responsibilities of the OPH include the coordination of 
cross-agency activities and the collaboration with federal agencies and pri-
vate entities to implement the GPMA initiatives.246  These initiatives in-
clude development of a strategic, long-term plan to advance research and 
development in personalized medicine and personalized medicine prod-
ucts, and to clarify and simplify the regulation of products used for per-
sonalized medicine to ensure that guidelines are consistent.247  The OPH 
would also recommend a clear delineation between the roles and responsi-
bilities of the FDA and the CMS in regulation and enforcement of prod-
                                                            
240 Dan Vorhaus, The Genomics and Personalized Medicine Act Returns to Congress, GENOMICS LAW 
REPORT (August 24, 2010), available at http://www.genomicslawreport.com/index.php/2010/08/24/the-
genomics-and-personalized-medicine-act-returns-to-congress/.  
241 Id.  
242 Presidential Commission for the Study of Bioethical Issues, supra note 147.    
243 Vorhaus, supra note 240.   
244 Genomics and Personalized Medicine Act of 2010, H.R. 5440, 111th Cong. (2D Sess. 2010)2d (May 27, 
2010).  
245 Id. at §101.  
246 Id. 
247 Id.  
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ucts used for personalized medicine, including laboratory-developed 
tests.248  
The GPMA also specifically addresses direct-to-consumer genetic 
testing.249  The Act directs the CDC to work in conjunction with the FDA 
and FTC to conduct an analysis of the public health impact of DTC mar-
keting of genetic tests, analyze the validity of claims made in marketing 
campaigns, and make recommendations to the OPH regarding the protec-
tion of the public from potential harm of DTC genomic tests.250  The Act 
also directs the FDA to collaborate with the FTC to identify and terminate 
advertising campaigns that make false, misleading, deceptive, or unfair 
claims regarding the risks or benefits of products used for personalized 
medicine.251   
For this current version of the bill to become law, it would likely 
require extensive revision as personalized medicine and the use of DTC 
genetic testing has grown exponentially in the last four years.  The topic of 
consent should be addressed in terms of the use of genomic data in future 
research.  The Act should mandate informed consent agreements that al-
low for future research in advance of clear research objectives but main-
tain the right of an individual to opt out of the research at any time.252  The 
FDA should be given clear guidelines as to the scope of its regulatory 
power and its priorities in the DTC genetic testing realm to ensure that its 
oversight is not counterproductive to the best interests of individuals and 
society by hampering research efforts. Unlike in the California Genetic In-
formation Privacy Act, civil and criminal penalties should only be availa-
ble in situations of intentional testing or use of genetic information without 





Proper legislation and regulation of DTC genetic testing can help 
to minimize various privacy concerns while allowing for the use of genetic 
data to further research in drug therapies, disease prevention, disease 
                                                            
248 Id.  
249 Id. 
250 Id.  
251 See Vorhaus, supra note 240 at 3.  While this was addressed in the GAO report around the same time as 
the introduction of the bill, the GAO’s investigation is frequently criticized for being an “unscientific snap-
shot” of the field of genomic testing.  
252Id. at 1..H.R. 5440. This language is contained in the GPMA in regard to obtaining consent for a pro-
posed national biobank. A similar consent structure would work well for private biobanks. 
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treatments and ultimately, to find genetic paths to cures.253  Last year saw 
the first use of emergency genome sequencing to aid in direct treatment.254  
Fourteen-year-old Joshua Osborn was rushed to the hospital with head-
aches, fever, and brain swelling so severe he was put in a medically in-
duced coma.255  After weeks of testing and even a brain biopsy, the doctors 
were no closer to discovering the cause of his illness.256  Then doctors de-
cided they would run one more test using an experimental DNA technolo-
gy and researchers’ newest genomic sequencing technique: next-
generation sequencing.257  Doctors prepared samples of Joshua’s cerebro-
spinal fluid and sent the samples to researchers at the University of Cali-
fornia, San Francisco for sequencing.258  After two days, the sequencers 
determined the sequences of three million fragments of DNA present in 
the boy’s samples.259  After removing the human DNA fragments, the re-
maining DNA was compared to sequencing data from the National Center 
for Biotechnology Information, an online host of genomic databases 
worldwide.260  Within just a few hours, the doctors discovered that Josh-
ua’s cerebrospinal fluid contained DNA from a potentially lethal bacte-
rium called Leptospira.261  While extremely difficult to discover, Leptospi-
ra is easily treated with penicillin and Joshua started to recover almost 
immediately.262  
Experts in the field are excited about the plethora of possibilities in 
the field of genomic testing.263  “Diagnosis is a crucial step in treating ill-
ness but can also be the most difficult.”264  In many situations, doctors can 
only guess at a diagnosis based on the symptoms and then run costly and 
time-consuming tests to determine the cause of the problem.265  Though 
further research is required, this case study shows DNA sequencing can be 
                                                            
253 Anne Wojcicki, A Note To Our Customers About The New Year, 23ANDMEBLOG (Jan. 12, 2015), at 
https://blog.23andme.com/news/announcements/a-note-to-our-customers-about-the-new-year/. 
254 Top Genetic Findings of 2014, 23ANDMEBLOG (December 26, 2014), at 
http://blog.23andme.com/news/top-genetic-findings-of-2014/; citing Carl Zimmer, In a First, Test of DNA 
Finds Root of Illness, N.Y. TIMES (June 4, 2014), available at 
http://www.nytimes.com/2014/06/05/health/in-first-quick-dna-test-diagnoses-a-boys-illness.html?_r=0. See 
Michael R. Wilson et. al., Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing, 370 
NEW ENG. J. MED. 2408 (2014). 
255 Wilson, supra note 254 at 2408. 
256 Zimmer, supra note 254. 
257 Id.; See supra notes 49-51 and accompanying text.  
258 Id. 
259 Id. 
260 Top Genetic Findings of 2014, supra note 254.   
261 Zimmer, supra note 254. 
262 Id.  
263 Id.  
264 Id.  
265 Id.  
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an immensely useful tool in diagnostics.266  Instead of performing multiple 
tests to search for the pathogen, DNA sequencing can reveal the pathogen 
immediately.267  Whether it is a virus, bacterium, fungus or parasite, just 
one test is needed.268   
This is just one example of the potential impact this may have on 
the future of genetic testing and research.  A Presidential Commission es-
poused this notion in its whole genome sequencing report stating that 
“[w]hole genome sequencing offers the promise of tremendous public 
benefit, and is expected to change substantially our ability to assess risk, 
diagnose, and treat disease.”269  Scientists predict that whole genome se-
quencing research will promote a better understanding of the genetic fac-
tors that contribute to the overall health of individuals.270  Whole genome 
sequencing will change how individuals manage their own health through 
personalized medicine, allowing physicians to tailor treatments and man-
age the health of individuals based on their genetic profiles.271  
The research conducted using publically available data also sup-
ports scientific entities that advance the common good by increasing eco-
nomic opportunities.272  The U.S. government invested billions of dollars 
in the Human Genome Project.273  This investment has generated $244 bil-
lion in personal income and $796 billion in overall economic impact.274  
Taking data from just 2010, human genome sequencing projects and relat-
ed research directly and indirectly generated over 300,000 jobs and $3.7 
billion in tax revenue.275  In addition to the vast public benefit of genomic 
research, the economic impact of promoting scientific innovation is also 
significant.  Ensuring this kind of impact continues to propagate through-
out society should be a top priority of United States legislators and regula-
tory agencies.   
 
V.   CONCLUSION 
 
 The essence of the GPMA should be preserved: to secure the 
promise of personalized medicine for all Americans.  Regulation that pro-
                                                            
266 Id. 
267 Id.  
268 Id.  
269 Presidential Commission for the Study of Bioethical Issues, supra note 147, at 34.  
270 Id. at 35.  
271 Id.  
272 Id.  
273 Id.   
274 Id. at 36.   
275 Id.   
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motes improving the accuracy of disease diagnosis, increasing the safety 
of pharmaceuticals, preventing deceptive marketing practices, and ensur-
ing consent is openly and voluntarily given while expanding and accelerat-
ing genomics research is in the best interesting of every person and societ 
 
